Open House Originale Agreement for Ponesimod
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-26 - Ponesimod
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Offers/contracts cannot be submitted through the procurement portal; they must be sent by email with qualified electron...
Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal product and requires the stated AMG...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Oct 2027
- Supply arrangement for pharmaceutical products concerning the active substance Ponesimod.
- Open House original rebate contracts under Section 130c(1) SGB V.
Show full summary
This is a German Open House supply arrangement for pharmaceutical products, specifically Ponesimod, led by Techniker Krankenkasse with participating sickness funds. It is not a classic competitive award procedure: all suitable pharmaceutical companies meeting the stated conditions may join during the contract period. No estimated contract value is provided. The contract runs from 01.11.2025 to 31.10.2027 at the latest, with automatic earlier end if patent/market exclusivity expires. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the participation documents are only available electronically on the portal.
Risks
Offers/contracts cannot be submitted through the procurement portal; they must be sent by email with qualified electron...
Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal product and requires the stated AMG...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
- Applicant must have its seat in Germany, another EU Member State, or another EEA State.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Agreement for Ponesimod
Single lot for an Open House original rebate agreement for the active substance Ponesimod. Scope is nationwide in Germany. The arrangement is open to all suitable pharmaceutical companies that meet the stated legal and self-declaration requirements. No exclusivity and no individual negotiation apply. The lot information comes from structured data and the notice text.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Ponesimod zu schließen.
Value note
Show original TED data
Original lot title
Open House Originale Rabattverträge 2025-26 - Ponesimod
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zum Wirkstoff Ponesimod zu schließen.
Procurement Details
- Publication date
- 08 Sep 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 586433-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Belgium – Pharmaceutical products – Antimycotica
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
Offers/contracts cannot be submitted through the procurement portal; they must be sent by email with qualified electron...
Participation is limited to pharmaceutical entrepreneurs for the relevant medicinal product and requires the stated AMG...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications